Although their development has improved the selection of SCLC treatment methods, the immunotherapy effect is still limited due to the low expression of Programmed cell death 1 ligand 1 (PD-L1) and the occurrence of immunotherapy resistance. The gene discussed is CD274; the disease is small cell lung carcinoma.